On 19 March 2019 Protagen AG was acquired by Oncimmune Holdings plc.

For further information, please visit oncimmune.com

Improving Patient Immuno-Profiling

Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.

The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

Download the NavigAID SLE and/or NavigAID SSc whitepapers to find out more.

An area of perhaps even greater attention is immuno-oncology. This is a field that is currently exploding, and the quest to successfully treat and potentially cure cancer is truly the chance of a lifetime. However, many cancer immunotherapies have severe immune-related Adverse Events (irAEs) and are active only in a limited number of patients. Where limited treatment efficacy can be somewhat addressed by the implementation of combination therapies, this only increases the irAE challenge. Therefore, improved patient selection will enable the field of immunotherapy and precision medicine to reach its full potential.

In addition to its partnerships with pharmaceutical and biotechnology companies, Protagen’s strategic collaborations with world-leading institutes such as the National Center for Tumor Diseases (NCT) in Germany, the National Cancer Institute (NCI) in the USA and Gustave Roussy (GR) in France are enabling effective, targeted immunotherapeutic development to improve patient care.

Protagen’s vision of “selecting the right drug for the right patient” is establishing the company as a precision diagnostics leader in the fields of immuno-oncology and autoimmune disease—utilizing the complete value-generation chain from initial discovery through to validation and commercialization for improved patient management.

Download the immuno-oncology eBook to find out more.

Latest News from Protagen

Protagen have announced the appointment of Immuno-Oncology experts PD Dr. Jessica Hassel (National Center for Tumor Diseases, Heidelberg, Germany) and Dr. Aurélien Marabelle (Gustave Roussy, Paris, France) to its Scientific Advisory Board.

The EORTC Brain Tumor Group and Protagen have announced a collaboration to utilize Protagen’s Cancer Immunotherapy Array to investigate the immunological profile and immuno-competence of long-term Glioblastoma survivors.

The NCT and Protagen have announced a collaboration to utilize Protagen’s Cancer Immunotherapy Array to identify biomarkers that predict therapeutic response and the incidence of irAEs in urothelial carcinoma patients treated with checkpoint inhibitors.